Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
Key Highlights
- ➤U.S. Patent No. 12,751,991 granted for certepetide pancreatic cancer treatment methods
- ➤Patent expires May 2041, expanding certepetide intellectual property protection
- ➤Patent covers certepetide combinations with anti-cancer therapies for solid tumors
- ➤Lisata says added market exclusivity extends into November 2043
- ➤Lisata’s lead candidate MAR001 is in Phase 2b development for severe hypertriglyceridemia
Expert Statements
David J. Mazzo, Ph.D., Chief Executive Officer of Lisata Therapeutics
“This patent granted by USPTO secures important protection for the broad use of certepetide and provides added market exclusivity into November 2043, which is essential to support its continued development”
LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041.
The newly issued patent, titled “Methods for Treating Pancreatic Cancer and Other Solid Tumors,” expands Lisata’s intellectual property protection for certepetide. The patent covers administering the Company’s proprietary cyclic peptide in combination with at least one anti-cancer agent or therapy to treat pancreatic cancer and other solid tumors, including metastatic, refractory, and drug-resistant cancers, by treating, inhibiting, and/or reducing tumor volume.
Get started
Create a free account to read the full story.